az értekezés - Semmelweis Egyetem Doktori Iskola

28. James IF, Chavkin C, Goldstein A. (1982) Selectivity of dynorphin for κ opioid
receptors. Life Sci 31 (12–13): 1331-1334.
29. Waldhoer M, Bartlett SE, Whistler JL. (2004) Opioid receptors. Annu Rev Biochem 73:
953-990.
30. Nagase H. (2011) Chemistry of opioids. Topics in Current Chemistry, vol 299.
Springer, Heidelberg: 1-92.
31. Pasternak GW. (2001) Insights into mu opioid pharmacology - The role of mu opioid
receptor subtypes. Life Sci 68 (19-20): 2213-2219.
32. Schuller AGP, King MA, Zhang JW, Bolan E, Pan YX, Morgan DJ, Chang A, Czick
ME, Unterwald EM, Pasternak GW, Pintar JE. (1999) Retention of heroin and
morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-
1. Nat Neurosci 2 (2): 151-156.
33. Xu H, Partilla JS, de Costa BR, Rice KC, Rothman RB. (1993) Differential binding of
opioid peptides and other drugs to two subtypes of opioid δncx binding sites in mouse
brain: Further evidence for δ receptor heterogeneity. Peptides 14 (5): 893-907.
34. Clark JA, Liu L, Price M, Hersh B, Edelson M, Pasternak GW. (1989) Kappa opiate
receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel
kappa 3 subtype. J Pharmacol Exp Ther 251 (2): 461-468.
35. de Costa BR, Rothman RB, Bykov V, Jacobson AE, Rice KC. (1989) Selective and
enantiospecific acylation of kappa opioid receptors by (1S,2S)-trans-2-isothiocyanato-
N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl] benzeneacetamide. Demonstration of
kappa receptor heterogeneity. J Med Chem 32 (2): 281-283.
36. Rothman RB, France CP, Bykov V, De Costa BR, Jacobson AE, Woods JH, Rice KC.
(1989) Pharmacological activities of optically pure enantiomers of the kappa opioid
agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.
Eur J Pharmacol 167 (3): 345-353.
37. Jordan BA, Devi LA. (1999) G-protein-coupled receptor heterodimerization modulates
receptor function. Nature 399 (6737): 697-700.
38. Goldberg JS. (2010) Stereochemical basis for a unified structure activity theory of
aromatic and heterocyclic rings in selected opioids and opioid peptides. Persp Med
Chem 4: 1-10.
91